Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, Oppenheimer Analyst Says
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target increased by equities researchers at Oppenheimer from $12.00 to $20.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 217.46% from the stock’s previous close. A number […]
